In this issue: RDA article published in peer reviewed journal, a study in a new indication, UK health economic update and more…
In this issue: News on Quebec multi-centre trial, German Breast Group trial and Canine study, Professional conferences and more…
In this issue: In this issue….Clinical interest in RDA around the globe, RDA in canine cancer and Sudbury lab automation moving forward!
In this issue: Two new research studies related to RDA published in leading journals, clinical collaborations expanded, new RnaDx lab in Sudbury.
In this issue: New research shows RDA valuable in guiding chemotherapy treatment by predicting breast cancer survivability, RnaDx’ Toronto office relocates.
In this issue: Clinical findings presented with good reception in Cremona, Italy, opportunities for RDA in UK and Germany, Dr. Sanaa Noubir joins RnaDx as Clinical Development Manager.
In this issue: Ontario multi-centre clinical trial initiated, RDA™ receives significant interest at Triple Negative Breast Cancer Conference, economic study indicates RDA™ provides healthcare cost-savings.
In this issue: RDA™ Trial Initiated in Quebec, Math Talent Supports Rna Dx and Federal Funding to Advance RDA™.
In this issue: Clinical trials expand, new patents filed, business and clinical experts support RDA™
In this issue: Clinical trial underway, New trial planned for Teaching Hospital Network at McGill University, Clinical Research Collaboration with Instituti Ospitaliere di Cremona and updates on product development.
In this issue: Dr. Harry Bear appointed to Clinical Advisory Board, Clinical Trial Approved, Syndicated Angel Investor Round Closes, RnaDx to present at IMPAKT Breast Cancer Conference, Brussels, May 3-5